Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
IPO Year: 2016
Exchange: NASDAQ
Website: fulgentgenetics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/7/2023 | $35.00 | Neutral | UBS |
| 12/8/2022 | $65.00 → $40.00 | Overweight → Neutral | Piper Sandler |
| 11/18/2022 | $45.00 | Outperform | Raymond James |
| 8/25/2022 | $65.00 | Outperform | Credit Suisse |
| 2/4/2022 | $80.00 | Overweight | Piper Sandler |
| 1/25/2022 | $141.00 → $125.00 | Outperform | Oppenheimer |
| 8/10/2021 | $55.00 → $65.00 | Underperform | Credit Suisse |
| 8/5/2021 | $55.00 | Underperform | Credit Suisse |